Crescent Biopharma (CBIO) Cash & Equivalents (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Cash & Equivalents data on file, last reported at $189.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $189.2 million, up 743.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $189.2 million (up 743.39% YoY), and the FY2025 annual result was $213.2 million, up 513.22% from the prior year.
• Cash & Equivalents slipped to $189.2 million in Q1 2026 per CBIO's latest filing, from $213.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $213.2 million in Q4 2025 and troughed at $14.4 million in Q3 2024.
• A 5-year average of $69.5 million and a median of $50.5 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 70.85% in 2024, then surged 825.45% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $47.9 million in 2022, then retreated by 12.7% to $41.8 million in 2023, then fell by 16.81% to $34.8 million in 2024, then jumped by 513.22% to $213.2 million in 2025, then fell by 11.27% to $189.2 million in 2026.
• Business Quant data shows CBIO's Cash & Equivalents at $189.2 million in Q1 2026, $213.2 million in Q4 2025, and $133.3 million in Q3 2025.